Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

JAMA

Volumn 283, Issue 11, 2000, Pages 1460-1468

  Lieu, Tracy A ^a,b   Ray, G Thomas ^b   Black, Steven B ^c   Butler, Jay C ^e   Klein, Jerome O ^d   Brelman, Robert F ^f   Miller, Mark A ^g   Shinefield, Henry R ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DIVISION OF RESEARCH   (United States)

^c KAISER PERMANENTE   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e Artic Investigations Program   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g Vaccines and Biologicals   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ABSENTEEISM; ARTICLE; BACTEREMIA; BACTERIAL MENINGITIS; CHILD; COCHLEA PROSTHESIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; HEARING IMPAIRMENT; HUMAN; INFANT; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MORTALITY; OTITIS MEDIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TYMPANOSTOMY TUBE; UNITED STATES; VACCINATION;

EID: 0034653607     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.11.1460     Document Type: Article

References (54)

1. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med. 1997;337:970-976.
2. Klein JO. Otitis media. Clin Infect Dis. 1994;19: 823-833.
3. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831-1835.
4. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J. 1999;18:543-551.
5. Black S, Shinefield H. Progress toward effective pneumococcal vaccination in infancy. Contemp Pediatr. November 1998;(suppl):12-17.
6. Black SB, Shinefield HR, Fireman BH, et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine (Wyeth) in children. Pediatr Infect Dis J. In press.
7. Teele DW, Klein JO, Rosner B, et al. Epidemiology of otitis media during the first seven years of life in children in Greater Boston: a prospective, cohort study. J Infect Dis. 1989;160:83-94.
8. Hardy AM, for the Center for Health Statistics. Incidence and impact of selected infectious diseases in childhood. Vital Health Stat 10. 1991;180:10
9. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network, Streptococcus pneumoniae, 1998. Available at: http://www.cdc.gov/ ncidod/dbmd/abcs/survreports/spneu98.pdf. Accessibility verified February 4, 2000.
10. Capra AM, Lieu TA, Black SB, et al. The costs of otitis media in a managed care population. Pediatr In-fect Dis J. In press.
11. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctlve therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. JAMA. 1997;278:925-931.
12. Pomeroy SL, Holmes SJ, Dodge PR, et al. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. 1990;323:1651-1657.
13. Waltzman NJ, Scheffler RM, Romano PS. The Cost of Birth Detects. Lanham, Md: University Press of America Inc; 1996.
14. Severens JL, Brokx JPL, van den Broek P. Cost analysis of cochlear implants in deaf children in the Netherlands. Am J Otol. 1997;18:714-718.
15. Crabowsky M, Markowitz L. Serologic screening, mass immunization, and implications for immunization program. J Infect Dis. 1991;164:1237-1233.
16. Haddix A, Teutsch S, Shaffer P, et al, eds. A Practical Guide to Prevention Effectiveness: Decision and Economic Analyses. Atlanta, Ga: Centers for Disease Control and Prevention; 1994.
17. Gold MR, Siegel JE, Russell LB, et al, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
18. Kaplan SL, Mason EO, Barson WJ, et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics. 1998;102:538-545.
19. Zangwill KM, Vadheim CM, Vannier AM, et al. Epidemiology of invasive pneumococcal disease in Southern California: implications for the design and conduct of a pneumococcal conjugate vaccine trial. J Infect Dis. 1996;174:752-759.
20. Thompson D, Oster G, McGarry LJ, et al. Management of otitis media among children in a large health insurance plan. Pediatr Infect Dis J. 1999;18: 229-244.
21. Hall MJ, Lawrence L. Ambulatory surgery in the United States, 1996. In: Advance Data From Vital and Health Statistics, No. 300. Hyattsville, Md: National Center for Health Statistics; 1998:8-9.
22. Freed GL, Clark SJ, Konrad TK, et al. Variation in patient charges for vaccines and well-child care. Pediatr Adolesc Med. 1996;150:421-426.
23. Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 1999 rates; final rule, 63 Federal Register 40954 (1998).
24. Medical Fees in the United States. Los Angeles, Calif: Practice Management Information Corp; 1999.
25. American Medical Association. Physicians' Medicare Guide. Riverwoods, Ill: CCH Inc; 1998.
26. Centers for Disease Control and Prevention. National vaccination coverage levels among children aged 19-35 months: United States, 1998. MMWR Morb Mortal Wkly Rep. 1999;48:829-830.
27. Shinefield HR, Black S, Ray P. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999;18:757-763.
28. Cochi SL, Preblud SR, Orenstein WA. Perspectives on the relative resurgence of mumps in the United States. Am J Dis Child. 1988;142:499-507.
29. Nieminen T, Kaythy H, Leroy O, et al. Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr Infect Dis J. 1999;18:764-772.
30. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B, for the Active Bacterial Core Surveillance Team. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics [serial on-line]. March 1999;103:e28. Available at: http:// www.pediatrics.org/cgi/content/full/103/3/e28. Accessibility verified February 3, 2000.
31. Casper LM. Who's minding our preschoolers? current population reports. Available at: http:// www.census.gov/population/socdemo/child/p70-62/tab01.txt. Accessed May 1999.
32. Centers for Disease Control and Prevention. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 23. 1997;19:69.
33. Lieu TA, Cochi SL, Black SB, et al. Cost effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271:375-381.
34. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. JAMA. 1995;274:1201-1208.
35. Miller MA, Sutter RW, Strebel PM, et al. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276:967-971.
36. Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 1998;279:1371-1376.
37. Sorum PC. Measuring patient preferences by willingness to pay to avoid: the case of acute otitis media. Med Decis Making. 1999;19:27-37.
38. Oh PI, Maerov P, Pritchard D, et al. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther. 1996;18: 160-181.
39. Alsarraf R, Jung CJ, Perkins J, et al. Otitis media health status evaluation: a pilot study for the investigation of cost-effective outcomes of recurrent acute otitis media treatment. Ann Otol Rhinol Laryngol. 1998;107:120-128.
40. Butler JC, Breiman RF, Lipman HB, et al. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis. 1995;171:885-889.
41. Fiore AE, Levine OS, Elliott JA, et al. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis. 1999;5:828-831.
42. Bluestone CD, Klein JO. Otitis Media in Infants and Children. Philadelphia, Pa: WB Saunders Co; 1995: 229-230.
43. Makela PH, Leinonen M, Pukander J, et al. A study of the pneumococcal vaccine in prevention of clinically acute attacks of recurrent otitis media. Rev Infect Dis. 1981;3(suppl):S124-5132.
44. Halloran ME, Haber M, Longini IM, et al. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol. 1991;133:323-331.
45. The WHO Young Infants Study Group. Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatr Infect Dis J. 1999;18:S17-S22.
46. Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonvalent pneumococcal conjugate vaccine. J Infect Dis. 1999;180:1171-1176.
47. Obaro S, Leach A, McAdam KW. Use of pneumococcal polysaccharide vaccine in children. Lancet. 1998;351:1600-1601.
48. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis. 1999;5:336-345.
49. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth-Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente efficacy trial [abstract]. Pediatr Res. 1999;45:157A.
50. Byrns PJ, Bondy J, Glazner JE, et al. Utilization of services for otitis media by children enrolled in Medicaid. Arch Pediatr Adolesc Med. 1997;151:407-413.
51. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;217:375-381.
52. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104: 419-427.
53. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med. 1997;127:955-965.
54. Bureau of Labor Statistics. Consumer Price Index: all urban consumers. Available at: http:// stats.bls.gov/; http://146.142.4.24/cgi-bin/ surveymost. Accessed August 1999.